title: Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues.
abstract: The chemosensitivity of 43 human sarcoma tissues, including 18 osteosarcomas, 16 leiomyosarcomas and 9 liposarcomas, was compared with that of 28 adenocarcinomas of the stomach, using the in vitro succinate dehydrogenase inhibition (SDI) test. These tissues were exposed for 3 days to each antitumor drug, including adriamycin (ADM), 5-fluorouracil (5-FU), mitomycin C (MMC), cisplatin (CDDP), aclacinomycin A (ACR) and carboquone (CQ), them the cell viability was estimated based on the succinate dehydrogenase (SD) activity, determined using [3-(4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H tetrazolium bromide] (MTT). SD activity was significantly lower in the osteosarcoma as compared to that in the adenocarcinoma, for ADM, MMC, CDDP, ACR and CQ (p < 0.01), and was higher for ADM (p < 0.05) in cases of leiomyosarcoma and for CDDP (p < 0.01) and ACR (p < 0.05) in cases of liposarcoma. The sensitivity rate was higher in osteosarcoma than in adenocarcinoma for ADM, MMC and CDDP. These findings suggest that patients with osteosarcoma will probably show a fairly good response to antitumor drugs, and that when liposarcoma or leiomyosarcoma tumors show resistance to antitumor drugs, then resection at the time of initial exploration and combined modalities, including radiation and hyperthermia, should be considered.
authors.affiliation: Cancer Center of Kyushu University Hospital, Fukuoka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Takeuchi
authors.forename: H
authors.initials: H
authors.lastname: Baba
authors.forename: S
authors.initials: S
authors.lastname: Inutsuka
authors.forename: I
authors.initials: I
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Kusumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Maehara
authors.forename: K
authors.initials: K
authors.lastname: Sugimachi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000201:enzymology; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy / Q000201:enzymology; D008080:Liposarcoma / Q000188:drug therapy / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000188:drug therapy / Q000201:enzymology; D012509:Sarcoma / Q000188:drug therapy* / Q000201:enzymology; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D013385:Succinate Dehydrogenase / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D013385:Succinate Dehydrogenase